Longitudinal timepoint assessment of patient-reported clinical disease activity in ulcerative colitis and Crohn’s disease: suitability of a rapid Patient-Reported Outcome 2 (PRO-2) assessment
Year: 2026
Type: article
Abstract: BACKGROUND & AIMS: Patient-reported outcomes (PRO) are essential for monitoring disease activity and treatment response in inflammatory bowel disease (IBD). The conventional PRO-2 requires several days of prospective symptom recording, increasing participant burden and attrition in longitudinal research. We evaluated whether a "rapid PRO-2", using 2 days of data collected retrospectively and prospectively in a single day, could serve as a reliable and pragmatic alternative to a 4-day PRO-2. METHODS: Using data from the ongoing IBD-RESPONSE cohort (n = 684 Crohn's disease [CD]; n = 548 ulcerative colitis [UC]), we compared 4-day PRO-2 and rapid PRO-2 scores at baseline and 14 weeks post-therapy to assess disease activity, clinical (non) response and remission. RESULTS: At baseline, 87.1% (596/684) of CD and 88.7% (486/548) of UC patients remained in the same active/inactive disease activity category (Cohen's kappa: CD 0.715; UC 0.762; both P < .001). At week 14, 77% (CD; 195/252) and 83.1% (UC; 193/232) remained in the same non-response/response/remission category (Cohen's kappa: CD 0.653; UC 0.743; both P < .001). Discrepancies mainly involved adjacent category shifts (ie, between response and remission, or non-response and response), with minimal re-classification between remission and non-response (n = 7 CD and n = 2 UC). Greater symptom variability across the 4 days increased the likelihood of switching between remission and non-response (odds ratio [95% confidence interval], CD 5.0 [3.65-6.85]; UC 7.8 [5.6-11.0], both P < .001). Responsiveness to clinical change was comparable between instruments. CONCLUSIONS: The rapid PRO-2 retains essential symptom data and demonstrates strong agreement with the 4-day PRO-2, offering an alternative in longitudinal studies to minimize burden and attrition.
Source: Journal of Crohn s and Colitis
Authors: Lauren C Beck, Gregory R Young, Nicola J Wyatt, Robert J Mulligan, Robert D Lees, Chaonan Dong, Hannah Watson, Trevor Liddle, Ally Speight, Dean M Allerton, Victoria Hildreth, Naomi S McGregor, Ruth Wood, Mary Doona, Debbie Alexander, Samantha Baillie, Biljana Brezina, Beatriz Camesella Perez, Bessie Cipriano, Jessica Cordle, Dominic Devine, Alexander T Elford, Kay Goulden, Marie Green, Hannah Husband, Lorna Ingoe, Lauren John, Sunita Dias Juliao, Andrew King, Klaartje Kok, Yasmin Laidler, Isabel Laszczak, Sarah Lawrence, Irish Lee, Melanie Love, Julian Marchesi, Claire McQuillian, Helen Millage, Ibinye Minimah, Alison Moss, Felicia Onoviran, Christopher Palmer-Jones, Gareth C Parkes, Sally Payton, Jahleesha Pinney, Kiran Prabhu, Chandni Radia, Parizade Raymode, Juan de la Revilla Negro, Francesca Rosa, Lydia Scarlett, Mohammed T Sharip, Natalie Shields, Sreedhar Subramanian, Robert Varley, Busiswa Vuyelele-Titchmarsh, Valentina Toska, Kevin Whelan, Kate Wistance, Mark Yongco, Lisa Younge, Nick Powell, Johanne Brooks-Warburton, Rachel Cooney, Simon P Borg-Bartolo, Shaji Sebastian, Benjamin Disney, Jack J Satsangi, Alan Steel, Konrad Koss, James C Lee, Anjan Dhar, Dharmaraj Durai, Philip Harvey, Christian P Selinger, Alexandra J Kent, Jeffrey R Butterworth, Jimmy K Limdi, Melissa A Smith, Peter M Irving, Ajay M Verma, Ailsa L Hart, Emma Wesley, Ian L P Beales, Jiezel De Guzman, Praveen Rajasekhar, Tariq Ahmad, Jonathan Blackwell, Charlie W Lees, Fraser Cummings, Kamal V Patel, Miles Parkes, Christopher J Stewart, Luke Jostins-Dean, James O Lindsay, Vipul Jairath, Nicholas A Kennedy, Tim Raine, IBD-RESPONSE collaborators, Christopher A Lamb
Institutions: Newcastle University, Newcastle upon Tyne Hospitals NHS Foundation Trust, Western General Hospital, Institute of Genetics and Cancer, University of Edinburgh, St George’s University Hospitals NHS Foundation Trust, Oxford University Hospitals NHS Trust, Barts Health NHS Trust, Guy's and St Thomas' NHS Foundation Trust, Northumbria Healthcare NHS Foundation Trust, Northern Care Alliance NHS Foundation Trust, The Royal Wolverhampton NHS Trust, Royal Devon University Healthcare NHS Foundation Trust, University Hospitals Birmingham NHS Foundation Trust, Imperial College London, Taunton & Somerset NHS Foundation Trust, Somerset NHS Foundation Trust, Leeds Teaching Hospitals NHS Trust, Royal Free London NHS Foundation Trust, University Hospital Southampton NHS Foundation Trust, King's College Hospital NHS Foundation Trust, Kettering General Hospital, Kettering General Hospital NHS Trust, University Hospitals Sussex NHS Foundation Trust, King's College London, Shrewsbury and Telford Hospital NHS Trust, St Mark's Hospital, East and North Hertfordshire NHS Trust, University of Birmingham, Manchester University NHS Foundation Trust, Hull York Medical School, University of Oxford, Liverpool University Hospitals NHS Foundation Trust, East Cheshire NHS Trust, The Francis Crick Institute, University College London, County Durham and Darlington NHS Foundation Trust, Teesside University, Cardiff and Vale University Health Board, University of Manchester, Brighton and Sussex Medical School, Norfolk and Norwich University Hospital, Norfolk and Norwich University Hospitals NHS Foundation Trust, University of Exeter, University of Southampton, Kennedy Institute of Rheumatology, Queen Mary University of London, Western University, London Health Sciences Centre
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,790
Funders: Falk Foundation, Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Teva Pharmaceutical Industries, Leona M. and Harry B. Helmsley Charitable Trust, Boston Scientific Corporation, Wellcome Trust, Australian Government, Celltrion, National Institute for Health and Care Research, Department of Health and Social Care, Imperial College London, Imperial College Healthcare NHS Trust, Novo Nordisk, Dr. Falk Pharma, Medical Research Council, NIHR Imperial Biomedical Research Centre
OpenAlex ID: W7223218949